echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NEJM: A large number of patients with non-Hodgkin's lymphoma are still in remission after five years of CAR-T cell therapy

    NEJM: A large number of patients with non-Hodgkin's lymphoma are still in remission after five years of CAR-T cell therapy

    • Last Update: 2021-06-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    February 23, 2021 //---In a new study, researchers from Pennsylvania State University reported that in a clinical trial initiated by the Perelman School of Medicine at the University of Pennsylvania, a large number of non- Hodgkin's lymphoma (NHL) patients are still in remission five years after receiving chimeric antigen receptor (CAR) T cell (CAR-T) therapy (called Kymriah).




    The corresponding author of the paper, Dr.


    The co-authors of this study also include Dr.


    These researchers also studied the long-term persistence of CAR-T cells and found that 50% of patients experienced and maintained remission after the first year, the CAR19 transgene was not detected after five years, and 18 were infused with CAR-T Among the patients whose lymphoma recurred within one year, only one had lost the CAR19 transgene.


    These findings are a follow-up study of the same clinical trial published by Schuster and other researchers in the NEJM journal in 2017, and include patient treatment results collected at 28 months.


    Diffuse large B-cell lymphoma accounts for about 30% of all NHL, and it is estimated that there are 27,000 newly diagnosed DLBCL patients in the United States each year.


    References:


    References:

    1.
    Elise A.
    Chong et al.
    Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy .
    NEJM, 2021, doi:10.
    1056/NEJMc2030164.


    2.
    CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma
    https://medicalxpress.
    com/news/2021-02-car-therapy-long-lasting-remissions-non-hodgkin.
    html Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.